An independent private company
Created in 2010, Affilogic is an independent private company established in Nantes and specialized in the discovery and development of affinity proteins called Nanofitins®. Based on research in protein engineering at the Pasteur Institute and the CNRS, a process has been developed to generate this novel class of alternatives to antibodies.
Affilogic is extremely well integrated in its local environment, as a major member of the Atlanpole Biotherapies cluster in Nantes, one of the few French Bioclusters recognized by the government for its specific expertise in biotherapies and development of biotherapeutics. Olivier Kitten, Affilogic’s Founder & CEO, is a founder member of the biocluster, managing it and working for its recognition for 5 years, and is extremely familiar with local infrastructure and expertise. The company has signed a general collaboration framework agreement with the University of Nantes.
Based on an innovative technology : Nanofitins®
Based on research in protein engineering, a process has been developed to generate this novel class of alternatives to antibodies, able to bind and interact with a selected target. For any biological target, from peptides to entire cells, it is possible to generate custom Nanofitins® with high binding affinity and controlled specificity for detection, capture, or targeting purposes. Affilogic has exclusive and worldwide rights to this technology and performs custom discovery and development of Nanofitins® against nominated targets.
With international collaboration experience
Beyond the technological validation, Affilogic has demonstrated the platform’s economic potential by signing industrial contracts in the three main applications of Nanofitins®: diagnostic, bioprocessing and targeted therapy. The core strategy of Affilogic is the discovery and development of Nanofitins® for therapeutic applications. It is currently conducted (i) through early-stage collaborations with major multinational Pharma companies (on-demand discovery of Nanofitins®) with 70% export turnover, (ii) via sponsored research projects at the European Level (FP7 SADEL project, Horizon 2020 DiViNe project) or with the French Army (RAPID project Norofitines) and (iii) through internal R&D.